For instance, patients with lung cancer harboring the KIF5B‐MET fusion had responses of 8-10 months’ duration to crizotinib.11 A PR was noted in a 62‐year‐old woman with lung cancer harboring a STARD3NL‐MET gene fusion(69% reduction).14 ICC rarely exhibits MET fusions. The gene discussed is MET; the disease is intrahepatic cholangiocarcinoma.